| Title |
Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, May 2023
|
| DOI | 10.2147/ceor.s401687 |
| Pubmed ID | |
| Authors |
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi, Nupur Greene |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2023.
All research outputs
#22,835,295
of 25,462,162 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#488
of 525 outputs
Outputs of similar age
#347,525
of 407,956 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#17
of 17 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 407,956 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.